Related Experiment Videos
Targeted therapies: focus on a new strategy for gastrointestinal tumors
D Nicolella1, P Maione, C Gridelli
1Division of Medical Oncology, S.G. Moscati Hospital, Via Circumvallazione, Avellino 83100, Italy.
Abstract:
In the last few years the knowledge of molecular oncology has led to the development of many new biological agents whose targets are extracellular or intracellular molecules involved in the main signalling pathways that play major roles in cancer development. These agents represent a new approach to gastrointestinal malignancies, as for many other types of tumors; preliminary data show that targeted therapy may enhance activity of chemotherapeutic agents (i.e. cetuximab in metastatic colorectal cancer (CRC)) or be active as monotherapy (i.e. imatinib in gastro-intestinal stromal tumors). Despite the encouraging preclinical results, the majority of these compounds have not yet produced convincing clinical results. However, these new agents raise a new challenge in the treatment of gastrointestinal cancers, especially for CRC.
Insights
New targeted therapies in molecular oncology show promise for gastrointestinal cancers, including colorectal cancer (CRC). While preclinical data is encouraging, clinical results are still emerging for these novel biological agents.
Area of Science:
- Molecular oncology
- Gastrointestinal malignancies
- Cancer signaling pathways
Background:
- Advancements in molecular oncology have spurred the development of novel biological agents targeting key cancer pathways.
- These agents offer a new therapeutic strategy for gastrointestinal cancers, mirroring progress in other tumor types.
Purpose of the Study:
- To review the emerging role of targeted therapy in gastrointestinal malignancies.
- To assess the potential of these agents in enhancing chemotherapy or acting as monotherapy.
Main Methods:
- Review of preclinical and preliminary clinical data on targeted agents in gastrointestinal cancers.
- Analysis of specific examples like cetuximab in metastatic colorectal cancer (CRC) and imatinib in gastro-intestinal stromal tumors.
Main Results:
- Targeted therapy shows potential to enhance chemotherapeutic activity (e.g., cetuximab in CRC).
- Some agents demonstrate efficacy as monotherapy (e.g., imatinib).
- Despite promising preclinical findings, widespread convincing clinical results are not yet established.
Conclusions:
- Targeted agents represent a significant new challenge and opportunity in treating gastrointestinal cancers, particularly CRC.
- Further clinical validation is required to fully realize the potential of these molecularly targeted therapies.